Interleukin Genetics appoints Mark B. Carbeau as CEO and director
Interleukin Genetics, Inc., creator of PerioPredict, has announced the appointment of Mark B. Carbeau as chief executive officer and director. Kenneth S. Kornman, DDS, PhD, who has served as the president and CEO since August 2012, will continue to serve as president, chief scientific officer and a director.
Interleukin Genetics, Inc. (OTCQB: ILIU) has announced the appointment of Mark B. Carbeau as chief executive officer and director. Kenneth S. Kornman, DDS, PhD, who has served as the president and CEO since August 2012, will continue to serve as president, chief scientific officer and a director.
Mr. Carbeau has more than three decades of business expertise in the life science and health-care industries, as well as experience in diagnostics and pharmaceuticals. He also specializes in corporate strategies and business models to increase growth potential.
“On behalf of the board of directors of Interleukin Genetics, I am excited to welcome Mark Carbeau to the Company,” said James M. Weaver, chairman of the board of Interleukin Genetics. Mr. Weaver continued, “I would like to thank Ken for his years of service in the roles of president and CEO. As one of the founders and chief scientific officer of Interleukin, Ken has made many outstanding contributions to the Company, and has been an outspoken proponent of personalized medicine and an industry leader in the research, development and commercialization of genetics-based risk assessment products and services to improve healthcare. We look forward to benefiting from his continued scientific leadership.”
READ MORE | PerioPredict featured in Genome magazine
“I welcome the opportunity to lead Interleukin Genetics during this exciting time as we work toward our goal of providing more personalized care for the prevention of periodontal disease and other major human diseases,” said Mr. Carbeau. “I also look forward to working with the senior management team, all Interleukin colleagues and our provider partners to achieve our collective goal of improving patients’ lives.”
Prior to joining Interleukin, Mr. Carbeau was co-founder and CEO of Diagnostyx, a technology-based healthcare company focused on intelligent drug infusion systems. Prior to Diagnostyx, Mr. Carbeau served as CEO of PolyRemedy, a technology-enabled services business that combines health information technology with personalized therapeutics to improve wound-healing outcomes. He holds a BS in industrial engineering from Pennsylvania State University and an MBA from the Wharton School of the University of Pennsylvania.